The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF-κB signalling function.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
07
2020
accepted:
21
10
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
7
1
2022
Statut:
epublish
Résumé
The LIM-domain containing protein Ajuba and the scaffold protein SQSTM1/p62 regulate signalling of NF-κB, a transcription factor involved in osteoclast differentiation and survival. The ubiquitin-associated domain of SQSTM1/p62 is frequently mutated in patients with Paget's disease of bone. Here, we report that Ajuba activates NF-κB activity in HEK293 cells, and that co-expression with SQSTM1/p62 inhibits this activation in an UBA domain-dependent manner. SQSTM1/p62 regulates proteins by targeting them to the ubiquitin-proteasome system or the autophagy-lysosome pathway. We show that Ajuba is degraded by autophagy, however co-expression with SQSTM1/p62 (wild type or UBA-deficient) protects Ajuba levels both in cells undergoing autophagy and those exposed to proteasomal stress. Additionally, in unstressed cells co-expression of SQSTM1/p62 reduces the amount of Ajuba present in the nucleus. SQSTM1/p62 with an intact ubiquitin-associated domain forms holding complexes with Ajuba that are not destined for degradation yet inhibit signalling. Thus, in situations with altered levels and localization of SQSTM1/p62 expression, such as osteoclasts in Paget's disease of bone and various cancers, SQSTM1/p62 may compartmentalize Ajuba and thereby impact its cellular functions and disease pathogenesis. In Paget's, ubiquitin-associated domain mutations may lead to increased or prolonged Ajuba-induced NF-κB signalling leading to increased osteoclastogenesis. In cancer, Ajuba expression promotes cell survival. The increased levels of SQSTM1/p62 observed in cancer may enhance Ajuba-mediated cancer cell survival.
Identifiants
pubmed: 34735553
doi: 10.1371/journal.pone.0259556
pii: PONE-D-20-23722
pmc: PMC8568271
doi:
Substances chimiques
NF-kappa B
0
SQSTM1 protein, human
0
Sequestosome-1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0259556Déclaration de conflit d'intérêts
No authors have competing interests.
Références
J Clin Invest. 2008 May;118(5):1858-66
pubmed: 18382763
J Bone Miner Res. 2006 Jul;21(7):1136-45
pubmed: 16813535
J Biol Chem. 2003 Jan 10;278(2):1220-8
pubmed: 12417594
Curr Osteoporos Rep. 2014 Sep;12(3):263-71
pubmed: 24988994
Trends Biochem Sci. 2007 Feb;32(2):95-100
pubmed: 17174552
J Cell Biol. 2005 Feb 28;168(5):813-24
pubmed: 15728191
J Biol Chem. 2007 Jan 5;282(1):39-48
pubmed: 17092936
FEBS J. 2019 Jan;286(1):8-23
pubmed: 30499183
Mol Cell Biol. 2005 May;25(10):4010-22
pubmed: 15870274
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2938-43
pubmed: 20133701
Oncogene. 2008 Jan 10;27(3):274-84
pubmed: 17621269
J Cell Physiol. 2018 Jun;233(6):4606-4617
pubmed: 29219182
Am J Pathol. 2006 Aug;169(2):503-14
pubmed: 16877352
Biochem Biophys Res Commun. 2005 Mar 18;328(3):728-38
pubmed: 15694407
J Bone Miner Res. 2009 Apr;24(4):632-42
pubmed: 19049332
Dev Cell. 2004 Feb;6(2):303-9
pubmed: 14960283
Bone. 2013 Feb;52(2):699-706
pubmed: 23117207
Curr Biol. 2010 Apr 13;20(7):657-62
pubmed: 20303269
Gene. 2018 Feb 20;644:148-154
pubmed: 29126926
Endocr Rev. 2013 Aug;34(4):501-24
pubmed: 23612225
Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31
pubmed: 15520811
Mol Cell Biol. 2005 May;25(10):3956-66
pubmed: 15870270
Cell Adh Migr. 2013 May-Jun;7(3):283-7
pubmed: 23590879
J Bone Miner Res. 2009 Jul;24(7):1216-23
pubmed: 19257822
J Bone Metab. 2014 May;21(2):85-98
pubmed: 25025000